<DOC>
	<DOC>NCT00300781</DOC>
	<brief_summary>The purpose of this study is to learn whether neratinib is safe and effective in treating women with advanced HER2+ (human epidermal growth factor 2) breast cancer.</brief_summary>
	<brief_title>Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer</brief_title>
	<detailed_description>Arm A: HER2 gene amplification and disease progression following at least 6 weeks of standard doses of Herceptin; Arm B: HER2 gene amplification and no prior Herceptin or HER2-targeted treatment.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Pathologic diagnosis of breast cancer and current stage IIIB, IIIC, or IV Progression following at least 6 weeks of standard doses of Herceptin (Arm A only) Overexpression of HER2 Tumor tissue available and adequate for analysis at screening At least one measurable lesion Prior treatment with Herceptin (Arm B only) More than 4 prior cytotoxic chemotherapy regimens Subjects with bone or skin as the only site of measurable disease Inadequate cardiac function Major surgery, chemotherapy, radiotherapy, investigational agents or other cancer therapy within 1 week of treatment day 1 Active central nervous system metastases Pregnant or breastfeeding women Inability to swallow the HKI272 capsules</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>phase 2</keyword>
	<keyword>HER2+ breast cancer</keyword>
	<keyword>monotherapy neratinib</keyword>
</DOC>